Paper Details

  1. Home
  2. Paper Details

Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.

Author: DodickDavid W, KellermanDonald J, SchmidtPeter C, TepperStewart J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effectiveness of zolmitriptan delivered through a skin patch (ADAM) for treating difficult-to-treat migraines, including those with severe pain, nausea, or late onset. The study aims to determine if this method is more effective than oral medication for these challenging migraine types.
Paper Details　
Original Abstract of the Article :
To understand the efficacy of zolmitriptan applied with Adhesive Dermally Applied Microarray (ADAM) in treating types of migraine (those with severe headache pain, the presence of nausea, treatment ≥2 hours after migraine onset, or migraine present upon awakening) that are historically considered to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590125/

データ提供：米国国立医学図書館（NLM）

Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches

This study explores the efficacy of zolmitriptan, delivered via a novel Adhesive Dermally Applied Microarray (ADAM) technology, in treating migraine headaches. Imagine a desert traveler seeking relief from a scorching sun – this is what migraine sufferers experience, desperately searching for effective treatment options. The authors focus on patients with difficult-to-treat migraines, a group often less responsive to traditional oral medications, exploring the potential of this innovative delivery method to provide relief.

A Novel Approach

The study investigates the potential of zolmitriptan delivered via ADAM, a novel approach that may overcome some of the limitations associated with oral medications. Imagine a desert oasis where water is delivered directly to the roots of thirsty plants – this is how ADAM works, providing a targeted and efficient delivery of the medication. The authors' research suggests that this innovative technology may offer a viable option for patients with difficult-to-treat migraines, potentially providing relief for those who have struggled to find effective treatment options.

Hope on the Horizon

This study offers a glimmer of hope for patients with difficult-to-treat migraines, exploring a promising new avenue for treatment. Like a desert oasis emerging from the arid landscape, this research offers a potential solution for those who have long sought relief. The authors' findings suggest that zolmitriptan delivered via ADAM may offer a more effective and patient-friendly approach to migraine management, potentially improving quality of life for those who struggle with this debilitating condition.

Dr. Camel's Conclusion

This research explores the potential of zolmitriptan delivered via ADAM as a novel approach to treating difficult-to-treat migraines. It's like a beacon of hope emerging from a vast and often unforgiving desert, offering potential relief for those who have struggled to find effective treatment options. The authors' findings suggest that this innovative technology may provide a more effective and patient-friendly approach to migraine management, offering a promising path toward improved quality of life for those who suffer from this debilitating condition.
Date :
  1. Date Completed 2020-06-22
  2. Date Revised 2020-06-22
Further Info :

Pubmed ID

30698272

DOI: Digital Object Identifier

PMC6590125

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.